ATNM
Actinium Pharmaceuticals, Inc.
There isn't enough reported data to score ATNM yet.
ATNM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
ATNM's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
ATNM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.9x | $1.03 | -35% |
| Fair | 3.3x | $1.17 | -27% |
| Expensive | 4.2x | $1.46 | -8.1% |
| Current | 4.5x | $1.59 | — |
Historical ranges are pointers, not guarantees.
ATNM's PE is 4.5x, but its earnings don't support one, so it isn't a reliable read right now.
ATNM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ATNM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ATNM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +$1.66 |
| Q1 2026 | -$0.76 | +$0.71 |
| Q4 2025 | -$1.09 | +$0.18 |
| Q3 2025 | -$1.10 | +$0.29 |
| Q2 2025 | -$1.31 | +$0.20 |
| Q1 2025 | -$1.47 | +$0.24 |
| Q4 2024 | -$1.27 | +$0.56 |
| Q3 2024 | -$1.39 | +$0.54 |
ATNM has returned to profit: it earned $0.35 per share over the past year, after losing money the year before.
ATNM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $45K | -81% |
| Q2 2022 | $45K | -83% |
| Q1 2022 | $940K | +51% |
ATNM's revenue is growing: $35M last quarter, up 77678% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 79% | N/A |
| Q3 2025 | -6324% | N/A |
| Q3 2022 | -21776% | -18999 points |
| Q2 2022 | -17444% | -15537 points |
| Q1 2022 | -549% | +314 points |
| Q4 2021 | -34991% | N/A |
| Q3 2021 | -2776% | N/A |
| Q2 2021 | -1908% | N/A |
ATNM's operating margin was 79% last quarter, up 628 points from the same quarter a year ago.
ATNM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$5.8M | +$1.7M |
| Q3 2024 | -$12M | -$820K |
| Q2 2024 | -$8M | +$5.7M |
| Q1 2024 | -$7.4M | +$7.8M |
| Q4 2023 | -$7.5M | +$304K |
| Q3 2023 | -$11.2M | -$5.4M |
| Q2 2023 | -$13.7M | -150% |
| Q1 2023 | -$15.2M | -$9.4M |
ATNM has burned cash in almost every quarter: −$29M over the past year, against −$34M the year before.
ATNM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +169K shares |
| 1 year | +0.7% | +211K shares |
| 3 years | +20% | +5.2M shares |
| 5 years | +55% | +11.2M shares |
| Available history | +477% | +26M shares |
ATNM has 31M diluted shares, up 0.7% from a year ago.
ATNM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -3.7x | Net Cash |
ATNM has more cash than debt.
ATNM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.9 | Neutral |
| Stochastic | 82.3 | Overbought |
ATNM's weekly RSI is 64 (neutral) and its Stochastic is 82 (overbought).
ATNM PE vs Healthcare Sector
| Metric | ATNM | Sector median | Relative |
|---|---|---|---|
| PE | 4.5x | 26x | 82% below |
ATNM is trading at 4.5x earnings, a 82% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ATNM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.33 | 20% above |
| 20 week MA | $1.14 | 39% above |
| 50 week MA | $1.19 | 34% above |
| 100 week MA | $1.32 | 20% above |
| 200 week MA | $3.86 | 59% below |
ATNM has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 59% below its 200-week average.
ATNM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.57 | $11.1 | +68% |
| 2021 | $11.1 | $6.66 | -40% |
| 2022 | $6.66 | $10.0 | +51% |
| 2023 | $10.0 | $5.08 | -49% |
| 2024 | $5.08 | $1.20 | -76% |
| 2025 | $1.20 | $1.52 | +27% |
| 2026 YTD | $1.52 | $1.59 | +4.6% |
ATNM has finished lower in three of the last six years. It's up 4.6% so far in 2026.